Soleno Therapeutics, Inc. (NASDAQ:SLNO) Financial Analysis

Core Insights - Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases, currently not generating significant revenue [1] - The company operates in a sector characterized by a focus on research and development rather than immediate profitability [5] Financial Metrics - Soleno's Return on Invested Capital (ROIC) is -15.74%, with a Weighted Average Cost of Capital (WACC) of 4.67%, resulting in a ROIC to WACC ratio of -3.37, indicating it is not generating returns that exceed its cost of capital [2] - In comparison, Akari Therapeutics has a ROIC of -64.44% and a WACC of 3.75%, leading to a ROIC to WACC ratio of -17.18, while Leap Therapeutics shows a ROIC of -37.62% and a WACC of 4.69, with a ratio of -8.02 [3] - Tenax Therapeutics has the highest ROIC to WACC ratio among peers at -4.39, despite a ROIC of -48.59% and a WACC of 11.07, suggesting it is relatively closer to covering its cost of capital [4] Industry Overview - All companies in the peer group, including Soleno Therapeutics, are experiencing negative ROIC, which is typical for clinical-stage biopharmaceutical companies in the investment phase [5]